Q-omics provides the consensus-scored LMAN1L profile across patient tissues and cancer cell-line models. LMAN1L expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LMAN1L is differentially expressed in 6, with the highest sampling consensus in STAD. Additionally, LMAN1L protein abundance shows 8,511 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, STAD, and HNSC as cancer lineages where LMAN1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LMAN1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LMAN1L survival associations across molecular data types. LMAN1L RNA expression shows survival associations in the most cancer types (18), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LMAN1L RNA expression–survival associations across cancer types. High LMAN1L expression shows unfavorable associations in KIRC, MESO, READ and OV, but favorable associations in STAD and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify KIRC as the clearest survival context for LMAN1L RNA expression.
This table summarizes LMAN1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 2. The strongest signals are observed in STAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for LMAN1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LMAN1L shows lower tumor expression in STAD, LUAD, ESCA and BLCA and higher tumor expression in KIRC and LUSC. The STAD box plot shows higher LMAN1L RNA expression in normal versus tumor tissue (log2 FC = −0.072, t-test p = .024).
This table shows molecular features associated with LMAN1L in patient tissues and cancer cell lines. In patient samples, LMAN1L shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, LMAN1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
